Replaces Prod. #: ALX-270-085
Selective inhibitor of cGMP-specific phosphodiesterase (PDE V, IC50=0.6µM).
Product Details
| Alternative Name: | 1-(3-Chlorophenylamino)-4-phenylphthalazine |
| |
| Formula: | C20H14ClN3 |
| |
| MW: | 331.8 |
| |
| CAS: | 78351-75-4 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by 1H-NMR and MS. |
| |
| Appearance: | Yellow solid. |
| |
| Solubility: | Soluble in DMSO (10mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | Ambient |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored, as supplied, at room temperature. Stock solutions are stable for up to 3 months at -20°C. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Local and long-range reciprocal regulation of cAMP and cGMP in axon/dendrite formation: M. Shelly, et al.; Science
327, 547 (2010),
Abstract;
cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo: H.L. Xu, et al.; Am. J. Physiol. Heart Circ. Physiol.
287, H2501 (2004),
Abstract;
Inhibitory effects of natriuretic peptides on vasopressin neurons mediated through cGMP and cGMP-dependent protein kinase in vitro: N. Akamatsu, et al.; J. Neuroendocrinol.
5, 517 (1993),
Abstract;
Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway: I.D. Durate, et al.; Eur. J. Pharmacol.
186, 289 (1990),
Abstract;
Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation: M. Hagiwara, et al.; J. Pharmacol. Exp. Ther.
228, 467 (1984),
Abstract;
